Characteristics of ACEi exposure
Patients were exposed to ACEi for a median of 23 (±103) months at
referral. ACEi were associated to another bradykinin-releasing drug in 5
patients (17%): 4 with dipeptidyl peptidase-4 inhibitors and 1 with
angiotensin-receptor blockers.